Facility Design and Engineering

Samsung Biologics plans to invest more than ₩1.9 trillion (US$1.5 billion) in the new Incheon, South Korea, facility, which will hold a manufacturing capacity of 180,000 L.

The new plasmid manufacturing facility aims to increase BioNTech’s autonomy and flexibility in manufacturing.

Single-use systems hold key benefits for biomanufacturers, despite certain limitations.

Catalent has completed the expansion of its clinical supply facility located in Shanghai, China.

By eliminating the waste involved in traditional approaches to project set-up and execution, integrated project delivery helps innovators in the European life sciences market meet their fast-track delivery targets.

In the all-too-common debate over building lab facilities versus outsourcing, the best strategy may be the middle ground: licensing.

The new Massachusetts facility will strengthen Cytiva’s cell culture services.

Cambrex has expanded its stability storage business, Q1 Scientific, in Ireland and Belgium.

Integrated project delivery can fast-track delivery targets by eliminating the waste involved in traditional approaches to project set-up and execution.

Civica is expanding in the greater Richmond-Petersburg region and investing $27.8 million in a new testing facility.

Grand River Aseptic Manufacturing has completed phase II of its facility expansion with the installation of two new sterile filling lines.

This article provides an overview of solutions to address key challenges facing vaccine developers or CDMOs wishing to build their own commercial-scale mRNA production facilities.

TFF Pharmaceuticals is expanding its R&D operations with a new facility in Austin, Texas.

Wacker is investing more than €100 million (US$100.5 million) to expand its Halle, Germany, site with an mRNA competence center.

Croda has entered into an agreement with the US government to support the expansion of its lipid systems capability.

REGENXBIO has opened a new in-house facility at its headquarters in Rockville, Md., that will be used to manufacture AAV gene therapies at commercial scale.

Astellas Pharma has opened its new gene therapy manufacturing facility in Sanford, NC, which will support clinical- and commercial-scale manufacturing of AAV vectors for gene therapies.

The expansion at Seqirus’ Holly Springs, N.C., manufacturing facility will support the formulation and fill/finish of influenza vaccines.

AGC Biologics is investing in viral vector suspension technology at its new Longmont, Colo., facility.

Catalent will invest $350 million into integrated biologics drug substance and drug product manufacturing at Bloomington, Indiana facility.

High Purity New England has launched its third facility, focused on single-use assemblies.

Achilles Therapeutics has announced that it will expand its clinical manufacturing capabilities in the UK and enter a partnership agreement for expansion in the US.

Tjoapack has doubled its packaging capacity with the completion of its Netherlands facility expansion.

VectorBuilder will expand with the construction of new $500 million Gene Delivery Research and Manufacturing Campus in Guangzhou, China.

INCOG Biopharma has completed the construction of its cleanroom production area, marking a milestone in the completion of an overall $100 million investment in a new facility.

Catalent has acquired the Vaccine Manufacturing Innovation Centre in Harwell, Oxford to expand its biologics capabilities across the UK and Europe.

Merck has expanded its manufacturing facility in Elkton, Va. to further increase its HPV vaccine supply.

UCB has announced it will build a new innovative gene therapy facility in Belgium.

A consortium of nine development partners will support Biovac's expansion of its existing vaccine manufacturing plant capacity, while Biovac itself aims to raise funds to boost increased vaccine manufacturing capacity across Africa.

Thermo Fisher Scientific is expanding its Millersburg, Penn., site with a $40 million investment to support increased production of single-use technology for critical vaccines and biologics.